Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement J P
Laboratoire de Pharmacologie, Faculté de Médecine, Créteil, France.
Invest New Drugs. 1996;14(2):147-51. doi: 10.1007/BF00210785.
The binding of docetaxel to human plasma proteins was studied by ultrafiltration at 37 degrees C and pH 7.4. Docetaxel was extensively (> 98%) plasma protein bound. At clinically relevant concentrations (1-5 micrograms/ml), the plasma binding was concentration-independent. Lipoproteins, alpha1-acid glycoprotein and albumin were the main carriers of docetaxel in plasma, and owing to the high interindividual variability of alpha1-acid glycoprotein plasma concentration, particularly in cancer, it was concluded that alpha1-acid glycoprotein should be the main determinant of docetaxel plasma binding variability. Drugs potentially coadministered with docetaxel (cisplatin, dexamethasone, doxorubicin, etoposide, vinblastine) did not modify the plasma binding of docetaxel. In blood, docetaxel was found to be mainly located in the plasma compartment (less than 15% associated to erythrocytes).
在37℃和pH 7.4条件下,通过超滤法研究了多西他赛与人血浆蛋白的结合情况。多西他赛与血浆蛋白广泛结合(>98%)。在临床相关浓度(1 - 5微克/毫升)下,血浆结合呈浓度依赖性。脂蛋白、α1 - 酸性糖蛋白和白蛋白是多西他赛在血浆中的主要载体,由于α1 - 酸性糖蛋白血浆浓度存在高度个体间变异性,尤其是在癌症患者中,因此得出结论,α1 - 酸性糖蛋白应是多西他赛血浆结合变异性的主要决定因素。可能与多西他赛联合使用的药物(顺铂、地塞米松、阿霉素、依托泊苷、长春碱)不会改变多西他赛的血浆结合情况。在血液中,发现多西他赛主要存在于血浆部分(与红细胞结合的比例小于15%)。